Nov 12, 2024 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. “The Mirum team executed across all aspects of the business in the third quarter with growth across all three commercial medicines highlighted by acceleration of LIVMARLI PFIC sales,” said Chris…
Nov 8, 2024 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,100 shares of common stock and 28,050 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement…
Nov 7, 2024 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Visit the Investors and Media section of Mirum’s corporate website for webcast links and…
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 Nov 4, 2024 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter…
Nov 14, 2024 – Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San Diego, California.…
2024-03-04 Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG Initial data from adult patients with PMM2-CDG showed promising evidence of clinical benefit with GLM101 Notable improvements were seen in ataxia, one of the most frequent disease-associated clinical symptoms Data from this study provides key insights into future planned clinical trials…
